Glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide, semaglutide) and sodium-glucose cotransporter-2 (SGLT2) inhibitors are recognized for their effectiveness in controlling hyperglycemia and mitigating cardiovascular risk in individuals with type 2 diabetes (21). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.